CBX7

Across TCGA pan-cancer cohorts, CBX7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CBX7 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CBX7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CBX7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where CBX7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.248	0.925	.006	15	view →
CCRCC	DFS	Tertile	III,IV	0.906	0.531	.018	7	view →
GBM	DFS	Quartile	All	0.691	0.133	.029	3	view →
LSCC	OS	Median	All	0.812	1.000	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CBX7–LUAD (DFS)

Open the LUAD breakdown →